The Impact of PF-ILD on Our Patients

0 Lessons


You must be logged in to complete this course.

NOTE: Log in with your RNS account to take the course & evaluation
Not a member? Become one today or create a free guest account.

Log in now

Start Course


Nancy Eisenberger, DNP, FNP-C
Nurse Practitioner
Arthritis, Rheumatic and Back Disease Associates
Voorhees, New Jersey

Jessica Glennie, MSN, APRN
Cleveland Clinic, ILD Center
Cleveland, OH

Target Audience

This activity has been designed to meet the educational needs of rheumatology nurses, nurse practitioners, and physician assistants. Other healthcare providers may also participate.

Learning Objectives and Goals:

Upon completion of this activity, participants should be able to:

  1. Identify diagnostic tools that may be used to assess and monitor patients at risk for the development of progressive fibrosing interstitial lung disease (PF-ILD)
  2. Select appropriate questions to ask patients diagnosed with PF-ILD to uncover quality of life issues

Accreditation Statement

Rheumatology Nurses Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (Provider No. P0500).

Participants will receive 0.5 hours of continuing nursing contact hours by completing the education,completing an online evaluation, and receiving a post-test score of 70%.

Disclosure Statement

According to the disclosure policy of RNS, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

Relationships are abbreviated as follows: E, Educational planning committee; G, Grant/research support recipient; A, Advisor/review panel member; C, Consultant; S, Stock shareholder; SB, Speaker bureau; PE,Promotional event talks; H, Honoraria; O, Other

Planners, reviewers, and faculty have disclosed no conflicts of interest related to the content of this education with the exception of the following:
Nancy Eisenberger, DNP, FNP-C: Janssen (A, SB), AbbVie (SB, C), Lilly ( C), Novartis ( C) Jessica Glennie, MSN, APRN: Boehringer Ingelheim (SB) United Therapeutics (SB)

Planning Committee

Kim Cheramie, MSN, RN-BC, Accredited Provider Program Director, Rheumatology Nurses Society, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Scott Kober, MBA, Managing Partner, Excalibur Medical Education, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Kevin Lyons, Executive Director of the Rheumatology Nurses Society and Chief Executive Officer of Lyons Den Solutions, LLC, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Off-Label Product Disclosure

This activity will not include a discussion of off-label or investigational use of products.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE contact hours for your participation, please complete the post-test (achieving a passing grade of 70% or greater), and program evaluation. Your certificate can be printed immediately.


This activity is supported by an educational grant from Boehringer Ingelheim.


This course will expire on December 11, 2024.